Literature DB >> 27115842

Extending the market exclusivity of therapeutic antibodies through dosage patents.

Ulrich Storz1.   

Abstract

Dosage patents are one way to extend the market exclusivity of an approved drug beyond the lifetime of the patent that protects the drug as such. Dosage patents may help to compensate the applicant for the long period where the active pharmaceutical ingredient as such is already under patent prosecution, but not on the market yet, due to lengthy development and approval procedures. This situation erodes part of the time the drug is marketed under patent protection. Dosage patents filed at a later date can provide remedy for this problem. Examples of successful and unsuccesful attempts, and the reasons for the respective outcomes, are provided in this article.

Keywords:  Dosage; fractionation; inventive step; patent; rituximab; trastuzumab

Mesh:

Substances:

Year:  2016        PMID: 27115842      PMCID: PMC4968089          DOI: 10.1080/19420862.2016.1180491

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  5 in total

1.  Roche plans for more convenient-to-use Herceptin and Rituxan.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2010-04       Impact factor: 54.908

2.  Gemtuzumab ozogamicin: time to resurrect?

Authors:  Farhad Ravandi; Elihu H Estey; Frederick R Appelbaum; Francesco Lo-Coco; Charles A Schiffer; Richard A Larson; Alan K Burnett; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

3.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

Review 4.  Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.

Authors:  Tetsuya Tanimoto; Masaharu Tsubokura; Jinichi Mori; Monika Pietrek; Shunsuke Ono; Masahiro Kami
Journal:  Invest New Drugs       Date:  2012-09-11       Impact factor: 3.850

5.  Role of rituximab in first-line treatment of chronic lymphocytic leukemia.

Authors:  Jeffrey Bryan; Gautam Borthakur
Journal:  Ther Clin Risk Manag       Date:  2010-12-22       Impact factor: 2.423

  5 in total
  3 in total

1.  Old drug, new clinical use, no man's land for the indication: an awareness call from European experts.

Authors:  Stefan Rauh; Leonidas Mavroeidis; Panagiotis Ntellas; Ioanna Gazouli; Stefania Gkoura; Alexandra Papadaki; Davide Mauri; Yannis Metaxas; Jean-Yves Douillard; George Pentheroudakis
Journal:  ESMO Open       Date:  2020-09-30

Review 2.  US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives.

Authors:  Shawn Shouye Wang; Yifei Susie Yan; Kin Ho
Journal:  Antib Ther       Date:  2021-11-18

3.  An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

Authors:  Evelien Moorkens; Arnold G Vulto; Isabelle Huys
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.